Nov 17, 2020 / 07:00PM GMT
Annabel Samimy - Stifel Nicolaus - Analyst
Hi, good afternoon, everyone, and welcome to the Revance presentation. I am Annabel Samimy, biopharmaceutical analyst here at Stifel. And it's our pleasure to have Mark Foley with us today, CEO of Revance, as well as Toby Schilke, who is somewhere in a box I think on this platform.
So, as we look at Revance today, you are literally jumping into a commercial transition with the launch of your aesthetics platform that includes both fillers and a fintech platform, and you are about to add another with -- I'm going to stay within six months because we're not quite sure. So, why don't I just step back, let you guys have a five minute state of affairs -- brief state of affairs of where Revance is right now and we'll just launch into Q&A.
Mark Foley - Revance Therapeutics, Inc. - President & CEO
Sounds good. Thanks, Annabel. We really appreciate the opportunity to be here. So, I think just stepping back, this has been truly a transformational year for Revance. If you think of where we were this time last year,
Revance Therapeutics Inc at Stifel Virtual Healthcare Conference Transcript
Nov 18, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers